Osmotica Pharmaceuticals is a holding company. Through its subsidiaries, Co. is focused on the development and commercialization of products that target markets with underserved patient populations. Co.'s promoted products include: M-72, which is for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 to 65; Arbaclofen ER, which is for the treatment of multiple sclerosis spasticity; and OS870, which is for the treatment of neurodegenerative disorder. Co.'s non-promoted products include Methylphenidate ER, which is for the treatment of ADHD and Venlafaxine ER tablets, which is for the treatment of depressive disorder and social anxiety disorder. We show 13 historical shares outstanding datapoints in our OSMT shares outstanding history coverage, used to compute OSMT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing OSMT market cap history over the course of time is important for investors
interested in comparing OSMT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of OSMT versus a peer is one thing; comparing
OSMT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like OSMT can fluctuate over the course of history.
With this page we aim to empower investors researching OSMT by allowing them to research the OSMT market cap history. |
Free OSMT Email Alerts:
Video: The Importance of Market Cap
